menu
    • menu
    [{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"LPS","graph1":"Oncology","graph2":"Preclinical","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panavance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Misetionamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Panavance Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Misetionamide

    Menu

    Misetionamide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Misetionamide,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Panavance Updates on Misetionamide Phase 1 Trial in Pancreatic Cancer

                            Details : GP-2250 (misetionamide) is being evaluated in the early-stage clinical trial studies in combination with gemcitabine for the treatment of panmcreatic cancer.

                            Brand Name : GP-2250

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 09, 2024

                            Lead Product(s) : Misetionamide,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Misetionamide,Cisplatin,Mitomycin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatmen...

                            Details : GP-2250, a new therapeutic agent demonstrated promising antineoplastic effects on malignant mesothelioma cells in vitro, especially in combination with cisplatin/mitomycin C.

                            Brand Name : GP-2250

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2022

                            Lead Product(s) : Misetionamide,Cisplatin,Mitomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Misetionamide,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer

                            Details : GP-2250 is the Company’s broadly active, tumor cell selective cancer therapeutic with a unique mechanism of action that, as demonstrated in preclinical research, suppresses cancer cells by disrupting their energy metabolism—bringing about cancer cell...

                            Brand Name : GP-2250

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 28, 2022

                            Lead Product(s) : Misetionamide,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Panavance Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Misetionamide,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatm...

                            Details : Combination therapy of GP-2250 and gemcitabine proved to be effective for the treatment of pancreatic neuroendocrine tumors in vitro and in vivo, without the development of secondary resistances.

                            Brand Name : GP-2250

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : Misetionamide,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth